Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024 ...Middle East

HONG KONG, Sept. 8, 2024 /PRNewswire/ -- Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in combination with chemotherapy, for the perioperative...

Hence then, the article about perioperative ivonescimab pd 1 vegf for nsclc demonstrated clinically significant phase ii results presented in oral session at wclc 2024 was published today ( Sunday 08/09/2024 - 09:21 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024 )

Also on site :

• Nancy Guthrie News: Detective Worries She Had Medical Emergency During Kidnapping Ordeal
• Paris’ Eeriest Attraction Finally Reopens After Being Shut Down for 5 Months— Here’s What Tourists Need To Know
• Jack Innanen Has ‘Had Some Conversations’ About Joining Season Two of ‘Heated Rivalry’